BSN Capital Partners’s Merck MRK Stock Holding History

BSN Capital Partners’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-264,734	Closed	-$26.1M	–	13
2024 Q4	$26.1M	Buy	+264,734	New	+$27.3M	1.04%	11

Other funds holding MRK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BSN Capital Partners's MRK Position: Q1 2025 in Review

BSN Capital Partners sold out of Merck (MRK) in Q1 2025, closing a stake of 264,734 shares — an estimated $26.1M sold.

BSN Capital Partners first reported a position in MRK in Q4 2024 and held it in 1 quarter. The position peaked at $26.1M in Q4 2024. 3,447 funds tracked by Wall St. Rank hold MRK as of Q1 2025.

BSN Capital Partners reported no remaining Merck position as of Q1 2025 after selling out during the quarter.
BSN Capital Partners sold 264,734 Merck shares in Q1 2025, an estimated $26.1M.
BSN Capital Partners first reported a position in Merck in Q4 2024 and held it in 1 quarter.
BSN Capital Partners's Merck position peaked at $26.1M in Q4 2024.
3,447 funds tracked by Wall St. Rank held Merck as of Q1 2025.

Based on BSN Capital Partners's 13F filing for Q1 2025, filed 14 May 2025.